Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
复制标题
作者：
Amer AM;Zaid M;Chaudhury B;Elganainy D;Lee Y;Wilke CT;Cloyd J;Wang H;Maitra A;Wolff RA;Varadhachary G;Overman MJ;Lee JE;Fleming JB;Tzeng CW;Katz MH;Holliday EB;Krishnan S;Minsky BD;Herman JM;Taniguchi CM;Das P;Crane CH;Le O;Bhosale P;Tamm EP;Koay EJ
评估胰腺导管腺癌（PDAC）对治疗的反应仍然具有挑战性。本研究的目的是探讨肿瘤/实质界面的改变是否与反应有关。对治疗前后的计算机断层扫描（CT）进行了4个队列的回顾：队列1（99例接受新辅助放化疗和手术的I/II期PDAC患者）；队列2（86名接受化疗的IV期PDAC患者），队列3（94名接受基于方案的新辅助吉西他滨放化疗的I/II期PDAC患者）和队列4（47名接受新辅助放化疗的I/II期PDAC患者，在登记中进行前瞻性随访）。治疗后，肿瘤/实质界面在视觉上分为I型反应（界面保持不变或变得明确）或II型反应（界面变得不明确）。进行了共识（队列1‐3）和个体（队列4）视觉评分。使用专有平台量化界面增强的变化。在队列1中，I型应答者获得完全或接近完全病理应答的可能性更大（21% vs 0%; P = 0.01）。在队列1、2和3中，I型应答者的无病生存期和总生存期明显较长，与结果的传统协变量以及基线和标准化癌症抗原19‐9水平无关。在队列4中，2名高级放射科医生的κ值为0.8，接口评分与总生存率相关。定量方法显示了将患者分为I型或II型应答者的高特异性和敏感性（队列1的接受者工作曲线下面积为0.92，队列2为0.96，队列3为0.89）。PDAC/实质界面的变化可以作为对治疗反应的早期预测因子。癌症2018;124:1701量9。©2018作者。《癌症》由Wiley期刊公司代表美国癌症协会出版。这是一篇遵循知识共享署名-非商业-禁止衍生许可证条款的开放获取文章，该许可证允许在任何媒体上使用和分发，前提是正确引用原始作品，非商业用途，并且不进行修改或改编。胰腺癌的影像学特征表明对细胞毒性治疗有反应。这可能有助于作为临床试验反应的早期预测指标，并决定是否改变治疗。
The assessment of pancreatic ductal adenocarcinoma (PDAC) response to therapy remains challenging. The objective of this study was to investigate whether changes in the tumor/parenchyma interface are associated with response. Computed tomography (CT) scans before and after therapy were reviewed in 4 cohorts: cohort 1 (99 patients with stage I/II PDAC who received neoadjuvant chemoradiation and surgery); cohort 2 (86 patients with stage IV PDAC who received chemotherapy), cohort 3 (94 patients with stage I/II PDAC who received protocol‐based neoadjuvant gemcitabine chemoradiation), and cohort 4 (47 patients with stage I/II PDAC who received neoadjuvant chemoradiation and were prospectively followed in a registry). The tumor/parenchyma interface was visually classified as either a type I response (the interface remained or became well defined) or a type II response (the interface became poorly defined) after therapy. Consensus (cohorts 1‐3) and individual (cohort 4) visual scoring was performed. Changes in enhancement at the interface were quantified using a proprietary platform. In cohort 1, type I responders had a greater probability of achieving a complete or near‐complete pathologic response (21% vs 0%; P = .01). For cohorts 1, 2, and 3, type I responders had significantly longer disease‐free and overall survival, independent of traditional covariates of outcomes and of baseline and normalized cancer antigen 19‐9 levels. In cohort 4, 2 senior radiologists achieved a κ value of 0.8, and the interface score was associated with overall survival. The quantitative method revealed high specificity and sensitivity in classifying patients as type I or type II responders (with an area under the receiver operating curve of 0.92 in cohort 1, 0.96 in cohort 2, and 0.89 in cohort 3). Changes at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018;124:1701‐9. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. An imaging feature of pancreatic cancer is identified that indicates a response to cytotoxic therapies. This may be helpful as an early predictor of response for clinical trials and for deciding whether to change therapy.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
乳腺癌治疗veliparib-钙铂治疗的自适应随机化。
DOI：
10.1056/nejmoa1513749
发表时间：
2016-07-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Rugo HS;Olopade OI;DeMichele A;Yau C;van 't Veer LJ;Buxton MB;Hogarth M;Hylton NM;Paoloni M;Perlmutter J;Symmans WF;Yee D;Chien AJ;Wallace AM;Kaplan HG;Boughey JC;Haddad TC;Albain KS;Liu MC;Isaacs C;Khan QJ;Lang JE;Viscusi RK;Pusztai L;Moulder SL;Chui SY;Kemmer KA;Elias AD;Edmiston KK;Euhus DM;Haley BB;Nanda R;Northfelt DW;Tripathy D;Wood WC;Ewing C;Schwab R;Lyandres J;Davis SE;Hirst GL;Sanil A;Berry DA;Esserman LJ;I-SPY 2 Investigators
通讯作者：
I-SPY 2 Investigators
影响因子：
15.9
作者：
Koay, Eugene J.;Truty, Mark J.;Fleming, Jason B.
通讯作者：
Fleming, Jason B.
影响因子：
3.3
作者：
Wang, Yang;Qian, Bangping;Zhu, Bin
通讯作者：
Zhu, Bin
影响因子：
2.9
作者：
Bang, Seungmin;Chung, Hye Won;Song, Si Young
通讯作者：
Song, Si Young